Announced Sat, 12 Sept, 2026 · 10:14 IST
Molbio Diagnostics Q1 FY27 earnings call transcript filed with exchanges
MOLBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-6.0%1-day move
₹1406.70
prior close
₹1419.70
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-3.4-6.1-5.1-6.3-6.0-9.1-8.5-13.1-9.9-11.6+10.4———
Up moveDown movePending
AI summary
Molbio filed Q1 FY27 earnings call transcript held on September 8, 2026. Consolidated revenue stood at ₹408 crores with EBITDA of ₹104 crores at 25% margin and PAT of ₹52.7 crores. Management guided about 25% revenue growth and 24-25% EBITDA margin for FY27. OptraScan received US FDA approval in July 2026. Truenat platform covers 30 diseases across 90 plus countries with 12,500 plus machines. HPV program awaits rollout after AIIMS and WHO backed validation.
Likely market impact
Annual guidance of 25% revenue growth and stable margins offers clarity. OptraScan US FDA approval and HPV program are key future growth drivers.